- The shares of clinical-stage biotech GeoVax Labs ( NASDAQ: GOVX ) added ~16% in the morning hours Thursday in reaction to a peer-reviewed publication of an animal efficacy study on the company’s experimental vaccine for Sudan ebolavirus (SUDV).
- According to data posted on the Nature Partner Journals (NPJ) Vaccines, the vaccine named MVA-VLP-SUDV was found to generate 100% protection in guinea pigs against the virus with a single shot.
- A second vaccine dose further bolstered the vaccine responses of the animals, the company said, adding that all animals which received either one or two doses of MVA-VLP-SUDV developed protection against death and symptoms following a lethal dose of SUDV.
- “The resulting immune responses are broadly functional, involving both the antibody and T-cell effector function, resulting in optimal levels of efficacy, even with a single dose,” Chief Executive of GeoVax ( GOVX ) Mark J. Newman explained.
- The company is close to complete its ongoing study for the candidate involving nonhuman primates.
For further details see:
GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine